Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05291520 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants
A Phase 1 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT05291520 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 24 participants.
The verdict
NCT05291520, a Phase 1 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
An open-label, two part study to assess the safety, tolerability, and PK of VH3810109 in healthy adult participants. Participants will receive a single SC or IV dose of VH3810109 co-administered with rHuPH20 and will be followed up for 24 weeks.
Interventions
- BIOLOGICAL VH3810109
- BIOLOGICAL rHuPH20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-02-23 |
| Est. Completion | 2023-04-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05291520
The ClinicalTrials.gov registry entry for NCT05291520 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VH3810109 is the first listed.
NCT05291520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05291520 about?
NCT05291520 is a clinical study titled "A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants". An open-label, two part study to assess the safety, tolerability, and PK of VH3810109 in healthy adult participants. Participants will receive a single SC or IV dose of VH3810109 co-administered with rHuPH20 and will be followed up for 24 weeks.
What is the current status of trial NCT05291520?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-02-23. Estimated completion is 2023-04-10.
What interventions are being tested in trial NCT05291520?
The interventions under investigation include: VH3810109 (BIOLOGICAL), rHuPH20 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05291520?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.